Salix Pharmaceuticals / Oceana Therapeutics, Inc.

Fecal Incontinence (and pediatric Vesicoureteral Reflux)

$500M Solesta peak-sales potential cited by Salix CEO

Disease Overview

Fecal incontinence affects roughly 18 million US adults but is dramatically under-treated due to stigma. Treatment options range from dietary management and biofeedback to sacral neuromodulation and surgery. Vesicoureteral reflux (VUR) is the most common pediatric urological abnormality, where urine flows backward from bladder to kidneys, raising risk of pyelonephritis and renal scarring; treatment ranges from prophylactic antibiotics to ureteral reimplantation surgery.

Competitive Landscape

At deal time (Nov 2011) Solesta was the only injectable bulking agent FDA-approved for fecal incontinence, having gained PMA approval in May 2011. Competing options were conservative measures (fiber, biofeedback), Medtronic's InterStim sacral neuromodulator (FDA-approved for FI March 2011) at the higher-acuity end, and surgical sphincteroplasty. Salix CEO Carolyn Logan positioned Solesta as the middle-of-the-curve option that 'falls in between' surgery and pharmaceutical therapy with 'less risk of complications,' targeting peak sales >$500M. Deflux was the only FDA-approved endoscopic injectable for pediatric VUR grades II-IV, competing against open ureteral reimplantation surgery and chronic prophylactic antibiotics; it had ~$26M in 9M-2011 worldwide sales across 40+ countries. The deal complemented Salix's GI specialty sales force already calling on gastroenterologists and colorectal surgeons. In practice, Solesta uptake disappointed (post-approval real-world studies eventually showed durable but modest effect), and Salix itself was acquired by Valeant in 2015. Deflux remained a steady niche product later sold to Palette Life Sciences.